The SHIGETECVAX 3rd annual meeting was successfully held on 01 December 2022 in Washington, USA.
About 19 participants from the Austria (Eveliqure), Bangladesh (icddr,b), Germany (European Vaccine Initiative, EVI), Sweden (University of Gothenburg, UGOT), and USA (PATH), joined in person and virtually in a hybrid meeting to discuss the project achievements and confirm the strategy for the upcoming activities.
The consortium is strongly supported by the Members of the SHIGETECVAX Scientific and Ethics Advisory Committee towards its commitment to developing a new vaccine to protect against Shigella/ETEC infection.
Comments